Royalty Pharma plc
RPRX
Rank in Stocks
#894
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Share Price
$60.39
Last synced: 2026-10-19
Market Cap
$26.89B
Change (1 day)
-0.93%
Change (1 year)
64.87%
Country
US
Trade Royalty Pharma plc (RPRX)
Category
Healthcare
Earnings for Royalty Pharma plc (RPRX)
Earnings in Jun 2026 TTM: $1.35B
According to Royalty Pharma plc latest financial reports the company's current earnings are $1.35B. In 2024 the company made an earning of $1.33B, a decrease compared to its 2023 earnings that were of $1.70B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Royalty Pharma plc from 2015 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $1.35B | 1.94% |
| 2025 | $1.32B | -0.50% |
| 2024 | $1.33B | -21.72% |
| 2023 | $1.70B | 638.96% |
| 2022 | $230.06M | -81.46% |
| 2021 | $1.24B | -27.07% |
| 2020 | $1.70B | -30.85% |
| 2019 | $2.46B | 62.16% |
| 2018 | $1.52B | 13.00% |
| 2017 | $1.34B | 76.29% |
| 2016 | $761.90M | 0.42% |
| 2015 | $758.71M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | -10.73% |
HK
|
|
| $26.37M | -98.05% |
US
|
